• 약학회지
• /
• 제55권1호
• /
• pp.1-10
• /
• 2011

Mastic is a bleed resin formed in pistacia lentiscus tree extract form the anacatdiaceae family. Mastic is used as a food ingredient in the Mediteraanean resin, and has been used by local inhabitants as a traditional medicine for relief of upper abdominal discomfort, dyspepsiaand peptic ulcer. Clinically, mastic has been effective in the treatment of benign gastric and duodenal, ulcers, giving symptomatic relief and endoscopically proven healing. In this study, to enhance activiteies of poorly water soluble Mastic with oils, surfactants and cosurfactants and then the mixure was microemulsified in aqueous media under condition of gentle agitation and digestive motility that would be encountered in the gastrointestinal tract. Formulation development and screening were based on phase diagrams and characteristics of resultant microemulsion. For optimum mastic formulation, microemulsions with various ratio (w/w%) of mastics, oils, surfactants and cosurfactants were prepared and their solubility was evaluated by monitoring particles size in their buffer through visual asessment and electrophoretic light scattering spectrophotomerter (ELS). In vitro activity of self microemulsified mastic (SME mastic) was determined by minimum ingibition concentration (MIC) test against a panel of Helicobacter pylori (H. pylori) clinical strains. Additionally, in vivo activity of SME masitc was investigated us mouse infected by CH275 of H. pylori. The mean diameter of SME mastic was less then 100 nm in water and SME mastic was showed similar antiboisis effect compared to tometronidazole, clarithromycin and omeproazole. Consequently, SME mastic would be effective system to exterminate H. pylori. If mastic were dose with combined treatment, mastic might augur well for effect of H. pylori eradication as good remedy.

• 생명과학회지
• /
• 제17권5호
• /
• pp.723-727
• /
• 2007

본 연구는 H. pylori에서 metronidazole내성에 관여하는 유전자를 발견하고 이들 유전자들의 상호 조절 기전을 밝힘으로서 위장질환의 원인균인 H. pylori를 퇴치하기 위한 기본바탕을 마련하고자 수행되었다. 우선적으로 metronidazole 내성을 조절하는 유전자인 fdxA(ferredoxin)에 의한 metronidazole 내성 조절 기전을 밝히기 위하여 다음의 연구를 수행하였다. Type I 균주인 26695균주의 fdxA 유전자에 chloramphenicol 내성 유전자를 삽입하여 결손돌연변이주를 구축하였다. fdxA의 비활성화에 의한 rdxA 및 frxA 유전자의 발현을 알아보기 위하여 2-D electrophoresis와 MALDI-TOP-MS을 이용하여 fdxA 유전자의 비활성화에 의해 over-expressed protein과 under-expressed protein을 검색하였다. 본 실험의 결과로 type I 균주인 26695에서 fdxA 유전자를 비활성화시킨 결과 frxA 유전자의 발현양이 증가함을 northern으로 확인하였으며, 또한 fdxA유전자의 downstream에 위치한 유전자들이 H. pylori의 생존에 중요한 역할은 한다는 것을 알 수 있었다. 또한 2-D electrophoresis와 MALDI-TOP-MS을 이용하여 fdxA 유전자의 inactivation에 의해 over-expressed protein으로 nifU-like protein(HP0221), frxA(HP0642), nonheme ferritin(HP0653)와 아직 기능이 밝혀지지 않은 hypothetical protein(HP0902) 등이 발견되었다. 그리고 5'-methylthioadenosine/S-adenosylhomocysteine nucleosidase(HP0089), (3R)-hydroxymyristoyl ACP dehydratase(HP1376)과 thioredoxin(HP1458)등이 under-expressed protein으로 발견되었다.

• 대한소화기학회지
• /
• 제72권6호
• /
• pp.286-294
• /
• 2018

Background/Aims: The predictive factors of functional dyspepsia (FD) remain controversial. Therefore, we sought to investigate symptom responses in FD patients after Helicobacter pylori (H. pylori) eradication and used predictive factor analysis to identify significant factors of FD resolution at one-year after commencing eradication therapy. Methods: This prospective, multi-center clinical trial was performed on 65 FD patients that met Rome III criteria and had H. pylori infection. Symptom responses and factors that predicted poor response were determined by analysis one year after commencing H. pylori eradication therapy. Results: A total of 63 patients completed the one-year follow-up. When an eradication success group (n=60) and an eradication failure group (n=3) were compared with respect to FD response rate at one year, results were as follows; complete response 73.3% and 0.0%, satisfactory response 1.7% and 0.0%, partial response 10.0% and 33.3%, and refractory response 15.0% and 66.7%, respectively (p=0.013). Univariate analysis showed persistent H. pylori infection (p=0.021), female gender (p=0.025), and medication for FD during the study period (p=0.013) were associated with poor FD response at one year. However, age, smoking, alcohol consumption, and underlying disease were not found to affect response. Finally, multivariate analysis showed that female gender (OR, 4.70; 95% CI, 1.17-18.88) was the sole independent risk factor of poor FD response at one year after commencing H. pylori eradication therapy. Conclusions: Female gender was found to predict poor response in FD patients despite H. pylori eradication. Furthermore, successful H. pylori eradication appears to be associated with FD improvement, but the number of non-eradicated patients was too small to conclude.